A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516480-90-00

Acronym

XL184-401

Enrollment

Registered

2024-12-04

Start date

2015-11-23

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Medullary Thyroid Cancer

Brief summary

Progression free survival (PFS) per RECIST 1.1 per independent radiology review

Detailed description

Objective response rate (ORR) per RECIST 1.1 per independent radiology review

Interventions

DRUGCOMETRIQ 20 mg + 80 mg hard capsules

DRUGPL2

DRUGfilm-coated tablets

DRUGoral use

DRUGCABOMETYX 20 mg film-coated tablets

DRUGPL4

DRUGcapsule

DRUGhard

DRUGPL1

DRUGCOMETRIQ 20 mg hard capsules

DRUGCABOMETYX 60 mg film-coated tablets

DRUGPL3

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS) per RECIST 1.1 per independent radiology review	—

Secondary

Measure	Time frame
Objective response rate (ORR) per RECIST 1.1 per independent radiology review	—

Countries

Croatia, Hungary, Poland, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026